Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
Information source: Yokohama City University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Atrial Fibrillation
Intervention: Rivaroxaban (Drug); Dabigatran (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Yokohama City University Medical Center Official(s) and/or principal investigator(s): Kazuo Kimura, MD, Principal Investigator, Affiliation: Yokohama City University Medical Center
Overall contact: Kengo Tsukahara, MD, Phone: 81-45-261-5656, Email: k-tsuka@urahp.yokohama-cu.ac.jp
Summary
The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban
compared with dabigatran in patients with atrial fibrillation.
Clinical Details
Official title: Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study-
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: median variation of inflammatory markers (including high sensitivity C reactive protein, pentraxin3, interleukin-6, and interleukin-18) between at baseline and 12 months later in each treatment group
Secondary outcome: change over time of above inflammatory markers during 12 months follow-up period (at baseline, 1 month, 3 months, 6 months, and 12 months later) in each treatment group
Detailed description:
Previous study showed that administration of rivaroxaban reduced expression of
proinflammatory mediators in apolipoprotein E-deficient mice. However, it is unknown whether
the anti-inflammatory markers are decreased in patients with atrial fibrillation receiving
novel oral anticoagulants.
Eligibility
Minimum age: 20 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- non-valvular atrial fibrillation
- a CHADS2-VASc score of 1 or more
Exclusion Criteria:
- contraindication for rivaroxaban or dabigatran
- stroke or systemic embolism, acute coronary syndromes or peripheral artery disease
within 6 months before enrollment
- acute heart failure
- severe chronic renal failure (creatinine clearance < 30mL/min.)
- receiving dual antiplatelet therapy
- patients with a body weight of 50kg or less
- uncontrolled hypertension
- active malignancy, collagen disease, or infectious disease
- patients undergoing surgery within 6 months before enrollment
- patients who are planned to undergoing catheter ablation for atrial fibrillation
- patients who are not allowed to participate in the trial by judgement of the treating
physician
Locations and Contacts
Kengo Tsukahara, MD, Phone: 81-45-261-5656, Email: k-tsuka@urahp.yokohama-cu.ac.jp
Ashigara Kami Hospital, Ashigaura, Kanagawa 258-0003, Japan; Recruiting Izumi Kobayashi, MD, Phone: 81-465-83-0351, Email: eno_r@hotmail.com Izumi Kobayashi, MD, Principal Investigator
Chigasaki Municipal Hospital, Chigasaki, Kanagawa 253-0042, Japan; Recruiting Atsushi Wada, MD, Phone: 81-467-52-1111, Email: Chigasaki-circ@hotmail.co.jp Atsushi Wada, MD, Principal Investigator
Fujisawa City Hospital, Fujisawa, Kanagawa 251-8550, Japan; Recruiting Hideo Himeno, MD, Phone: 81-466-25-3111, Email: hdohimeno@jcom.home.ne.jp Hideo Himeno, MD, Principal Investigator
Fujisawa Shounandai Hospital, Fujisawa, Kanagawa 252-0802, Japan; Recruiting Takahiro Takei, MD, Phone: 81-466-44-1451, Email: t_takei@fj-shounandai.or.jp Takahiro Takei, MD, Principal Investigator
Hadano Red Cross Hospital, Hadano, Kanagawa 257-0017, Japan; Recruiting Reimin Sawada, MD, Phone: 81-463-81-3721, Email: rsawada@live.jp Reimin Sawada, MD, Principal Investigator
National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa 252-0392, Japan; Recruiting Yukiko Morita, MD, Phone: 81-42-742-8311, Email: y-morita@sagamihara-hosp.gr.jp Yukiko Morita, MD, Principal Investigator
International Goodwill Hospital, Yokohama, Kanagawa 245-0006, Japan; Recruiting Makoto Shimizu, MD, Phone: 81-45-813-0221, Email: makotoshimizuyaizu@gmail.com Makoto Shimizu, MD, Principal Investigator
Kanagawa Cardiovascular and Respiratory Disease Center, Yokohama, Kanagawa 236-0051, Japan; Recruiting Kazuki Fukui, MD, Phone: 81-45-701-9581, Email: Fukui@kanagawa-junko.jp Kazuki Fukui, MD, Principal Investigator
Nagatsuta kousei general hospital, Yokohama, Kanagawa 226-0027, Japan; Recruiting Takeshi Takamura, MD, Phone: 81-45-981-1201, Email: tkmrt@yokohama-cu.ac.jp Takeshi Takamura, MD, Principal Investigator
Saiseikai Yokohama City Southern Hospital, Yokohama, Kanagawa 234-8503, Japan; Recruiting Tsutomu Endo, MD, Phone: 81-45-832-1111, Email: endotu@nanbu.saiseikai.or.jp Tsutomu Endo, MD, Principal Investigator
Yokohama City University Hospital, Yokohama, Kanagawa, Japan; Recruiting Teruyasu Sugano, MD, Phone: 81-45-787-2800, Email: t_sugano@yokohama-cu.ac.jp Teruyasu Sugano, MD, Principal Investigator
Yokohama City University Medical Center, Yokohama, Kanagawa 232-0024, Japan; Recruiting Kazuo Kimura, MD, Phone: 81-45-261-5656, Email: c-kimura@urahp.yokohama-cu.ac.jp Kazuo Kimura, MD, Principal Investigator Kengo Tsukahara, MD, Sub-Investigator
Yokohama Seamen's Insurance Hospital, Yokohama, Kanagawa 240-8585, Japan; Recruiting Shunichi Kobayashi, MD, Phone: 81-45-331-1251, Email: shunichi_kobayashi@sempos.or.jp Shunichi Kobayashi, MD, Principal Investigator
Yokosuka City hospital, Yokosuka, Kanagawa 240-0195, Japan; Recruiting Jun Okuda, MD, Phone: 81-46-856-3136, Email: jokudajun@yahoo.co.jp Jun Okuda, MD, Principal Investigator
International University of Health and Welfare Atami Hospital, Atami, Shizuoka 413-0012, Japan; Recruiting Tomohiko Shigemasa, MD, Phone: 81-557-81-9171, Email: tshig@iuhw.ac.jp Tomohiko Shigemasa, MD, Principal Investigator
Omori Red Cross Hospital, Ohta, Tokyo 143-8527, Japan; Recruiting Yasuyuki Mochida, MD, Phone: 81-3-3775-3111, Email: y-mochi@u01.gate01.com Yasuyuki Mochida, MD, Principal Investigator
Additional Information
Starting date: July 2013
Last updated: August 4, 2015
|